AONC
American Oncology Network Inc.
11.10$
+0.0%
vs. previous close
Closing price · As of: Aug 19, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 0.3% | 0.2% | 0.1% | 74.2% | 0.9% | 0.5% | 75.7% | 74.2% | 76.8% | 71.1% | 68.7% | 70.5% | |
| 0.2% | 0.1% | 0.1% | 8.3% | 0.0% | 0.0% | 13.1% | 7.6% | 17.8% | 7.9% | 4.9% | 13.4% | |
| 0.2% | 0.1% | 0.1% | 11.3% | 0.0% | 0.0% | 19.7% | 17.1% | 24.9% | 12.8% | 4.9% | 15.4% | |
| – | – | 0.0% | 50.9% | 933.8% | 925.8% | 45.5% | 44.1% | 40.2% | 43.8% | 48.9% | 40.3% | |
| – | – | 0.0% | 11.2% | 164.6% | 215.9% | 9.6% | 11.9% | 10.5% | 12.6% | 12.5% | 12.9% | |
| – | – | – | 23.2% | 402.8% | 407.8% | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | 0.3% | – | 2.5% | 2.8% | 2.3% | |
| – | – | – | 0.4% | – | – | 0.3% | 0.0% | 0.3% | 0.6% | 0.6% | 0.5% | |
| 5.5% | 4.9% | 4.3% | 81.0% | 105.4% | 56.2% | 92.9% | 98.5% | 86.7% | 87.5% | 86.3% | 77.0% | |
| 0.3% | 0.3% | 0.6% | 43.2% | 37.2% | 44.6% | 42.6% | 45.1% | 55.4% | 53.8% | 50.6% | 46.1% | |
| – | – | – | 2.9% | 0.8% | 1.0% | 2.0% | 4.2% | 3.8% | 2.9% | 3.1% | 2.6% | |
| 0.3% | 0.3% | 31.7% | 32.6% | 19.4% | 629.8% | 30.6% | 34.1% | 44.6% | 44.0% | 39.4% | 36.3% | |
| – | – | – | 24.6% | – | – | 20.4% | 21.5% | 19.2% | 20.5% | 22.2% | 18.5% | |
| 94.5% | 95.1% | 95.7% | -4.4% | -5.4% | 43.8% | -86.6% | -43.2% | -24.3% | 5.8% | -9.8% | 4.0% | |
| -5.2% | -4.7% | -4.0% | 7.9% | -102.3% | -110.2% | -86.6% | -43.2% | -41.6% | -15.5% | -26.2% | -21.7% | |
| 12.5% | 12.5% | 12.4% | 12.8% | 49.6% | 49.1% | 1.7% | 1.8% | 1.8% | 2.4% | 3.4% | 2.9% |
Data as of: August 19, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.